drugset
drugset / Trial / NCT01993446

A Safety and Efficacy Study of DRM02 in Subjects With Rosacea

NCT01993446 ↗

Phase 2 Completed 30 enrolled Dermira, Inc.
RandomizedParallel-groupTriple-blindTreatment

Summary

The purpose of this study is to determine whether DRM02 is safe and effective in the treatment of rosacea when applied twice daily for 6 weeks.

Timeline

Start
2013-10
Primary completion
2014-02
Completion
2014-03

Drugs

EvaluationDrugModalityDoseRoute
Subject DRM02 Unknown 0.25 % Topical

Indications

rosacea